Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

JANX stock hub

Janux Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

JANXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

864.5M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

JANX

In the news

Latest news · JANX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-11.7

P25 -105.6P50 -46.5P75 -3.1

ROIC-9.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All JANX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

194

Groups with data

Currency

USD

Showing 194 of 194 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001817713
Company name	Janux Therapeutics, Inc.
Country	United States
Country code	US
Cusip	47103J105
Employees	109
Employees Change	33%
Employees Change Percent	43.42
Enterprise value	$-70.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-06-11
Isin	US47103J1051
Last refreshed	2026-05-10
Market cap	$864.5M
Market cap category	Small-Cap
Price	$14.18
Price currency	USD
Rev Per Employee	125,990.83x
Sector	Healthcare
Sic	2834
Symbol	JANX
Website	https://www.januxrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-13.24%
FCF yield	-9.08%
P/B ratio	0.92x
P/S ratio	62.95x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-113.9M
Net Income	$-114.5M
Net Income Growth Years	0%
Pretax Margin	-833.6%
Profit Per Employee	$-1.1M
ROA	-9.44
Roa5y	-10.41
ROCE	-16.2
ROE	-11.72
Roe5y	-14.99
ROIC	-9.82

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-44.87%
Cagr3y	-1.32%
EPS Growth Years	0
Revenue Growth	47.1x
Revenue Growth Years	0x
Revenue Growth3 Y	14.83x
Revenue Growth5 Y	104.93x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.01
Assets	$1B
Cash	$956.4M
Current Assets	$1B
Current Liabilities	$58.9M
Debt	$21.6M
Debt Equity	$0.02
Equity	$941.5M
Liabilities	$86.7M
Long Term Assets	$26.2M
Long Term Liabilities	$27.8M
Net Cash	$934.8M
Net Cash By Market Cap	$108
Net Cash Growth	-5.72%
Net Debt Equity	$-0.99
Tangible Book Value	$941.5M
Tangible Book Value Per Share	$15.47
WACC	17.96

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	17.01
Net Working Capital	$-10.8M
Quick ratio	16.95
Working Capital	$943.1M
Working Capital Turnover	$0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.22%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-44.84%
200-day SMA	19.46
3Y total return	-3.9%
50-day SMA	14.37
50-day SMA vs 200-day SMA	50under200
All Time High	71.71
All Time High Change	-80.23%
All Time High Date	2024-12-05
All Time Low	5.65
All Time Low Change	150.88%
All Time Low Date	2023-11-10
ATR	0.6
Beta	2.57
Beta1y	0.84
Beta2y	1.38
Ch YTD	2.72
High	14.65
High52	35.34
High52 Date	2025-11-26
High52ch	-59.89%
Low	13.88
Low52	12.12
Low52 Date	2026-02-05
Low52ch	16.96%
Ma50ch	-1.32%
Premarket Change Percent	-0.55
Premarket Price	$14.46
Premarket Volume	5,241
Price vs 200-day SMA	-27.17%
RSI	43.39
RSI Monthly	41.33
RSI Weekly	41.25
Sharpe ratio	-0.35x
Sortino ratio	-0.36
Total Return	-9.22%
Tr YTD	2.72
Tr1m	-5.06%
Tr1w	-1.15%
Tr3m	8.45%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	14
Analyst Count Top	6
Analyst Price Target Top	$48.67
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.52
Earnings Revenue Estimate	6,753,848x
Operating Income	$-157M
Operating margin	-1,143.1
Price target	$45.08
Price Target Change	$218
Price Target Change Top	$243

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	38,740,764%
Float Percent	63.53%
Shares Insiders	6.52%
Shares Institutions	78.35%
Shares Out	60,984,354
Shares Qo Q	0.84%
Shares Yo Y	9.22%
Short Float	19.2%
Short Ratio	6.25
Short Shares	12.2

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-117.3M
Average Volume	969,966.85x
Bv Per Share	15.47
CAPEX	$-945,000
Ch1m	-5.06
Ch1w	-1.15
Ch1y	-44.84
Ch3m	8.45
Ch3y	-3.9
Ch6m	-46.47
Change	-2.51%
Change From Open	-1.84
Close	14.54
Days Gap	-0.69
Depreciation Amortization	1,979,000
Dollar Volume	12,272,077.1
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-157M
EBITDA	$-155M
EPS	$-1.84
F Score	2
FCF	$-78.5M
FCF EV Yield	111.56x
FCF Per Share	$-1.29
Financing CF	7,936,000
Fiscal Year End	December
Founded	2,017
Investing CF	47,697,000
Ipr	-16.62
Iprfo	-58.31
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	17.97
Ma150ch	-21.12%
Ma20	14.89
Ma20ch	-4.78%
Net CF	-21,915,000
Next Earnings Date	2026-08-06
Open	14.44
Optionable	Yes
Position In Range	38.31
Post Close	14.18
Postmarket Change Percent	-0.25
Postmarket Price	$14.14
Ppne	21,416,000
Pre Close	14.54
Price Date	2026-05-08
Ptbv Ratio	0.92
Relative Volume	0.89x
Revenue	13,733,000x
SBC By Revenue	282.44x
Share Based Comp	38,788,000
Tr6m	-46.47%
Us State	California
Volume	865,755
Z Score	9.22

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does JANX pay a dividend?

Capital-return profile for this ticker.

Performance

JANX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns JANX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+78.3%

Float: +63.5% of shares outstanding

Insider ownership

+6.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

JANX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.4

Neutral momentum band

Price vs 200-day MA

-27.2%

50/200-day relationship not available

Beta (5Y)

2.57

More volatile than the market

Sharpe ratio

-0.35

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About JANX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current JANX stock rating?

Janux Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full JANX analysis?

The full report lives at /stocks/JANX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for JANX?

The latest report frames JANX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the JANX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.